Press Releases

New BioIVT Research Examines Potential Link Between HIV Integrase Inhibitor Drugs and Neural Tube Defects During Pregnancy

By Lauren Vagnone | August 15, 2019

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that researchers in its Transporter Sciences Group have co-authored a peer-reviewed DMD paper, which investigates the inhibitory effects of a class of HIV drugs known as integrase inhibitors on folate transporter pathways.
Read more

BioIVT to Host Symposium Highlighting Industry Progress in Immuno-oncology Drug Discovery Research

By Lauren Vagnone | August 7, 2019

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a research symposium entitled “Innovation in Immuno-oncology: Breaking Down the Barriers” on Aug. 14. This event, which will highlight research advances with implications for immuno-oncology drug discovery and clinical practice, will be held at the Dante Alighieri Society of Massachusetts in Cambridge, MA.
Read more

BioIVT Acquires Keystone Biologicals, Expands its Offering of Disease-state Biospecimens

By Lauren Vagnone | August 6, 2019

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Keystone Biologicals, Inc., a supplier of disease-state plasma, sera and controls, located in Hatboro, PA. This acquisition will expand BioIVT’s disease-state portfolio both by volume and product range.
Read more

BioIVT to Highlight Research Advances Made Using its Hepatocyte Products and Services at the 12th International ISSX Meeting

By Lauren Vagnone | July 23, 2019

BioIVT, a leading provider of research models and services for drug and diagnostic development, today outlined several scientific contributions that it will be making at the 12th International ISSX Meeting. This conference will be held from July 28-31 at the Oregon Convention Center in Portland, OR.
Read more

BioIVT to Host Webinar on How to Evaluate BSEP Inhibition and Reduce Drug-induced Liver Injury (DILI) Risk during Drug Development

By Lauren Vagnone | July 10, 2019

DILI is a leading cause of drug development failures and a frequent cause of drug label restrictions

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar that will present the latest in vitro research methods and International Transporter Consortium (ITC) guidance for assessing bile salt export pump (BSEP) inhibition to reduce and manage the risk of drug-induced liver injury (DILI) during drug development.
Read more

BioIVT HEPATOPAC® Meeting to Highlight Advances in Drug Discovery Research

By Lauren Vagnone | June 3, 2019

HEPATOPAC micropatterned hepatocyte cultures are optimized for drug safety, metabolism and efficacy research

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a HEPATOPAC Meeting at the AC Hotel by Marriott, San Francisco Airport/Oyster Point Waterfront on June 7. Presentations will show how the HEPATOPAC system can be employed in lead selection programs to investigate new drug candidates’ ADME-Tox profiles and assess their efficacy.
Read more

BioIVT Named Service Provider for Promega Immunotherapy Bioassays

By Lauren Vagnone | May 29, 2019

Demonstrating continuing support for immuno-oncology researchers, BioIVT extends excellence in research to help researchers screen novel therapeutics

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will now offer Promega Immune Checkpoint and antibody-dependent cell-mediated cytotoxicity (ADCC) Reporter Bioassays to support immunology and immuno-oncology research. This offering complements BioIVT’s custom assay development services using client-provided cells and reagents.Read more

New BioIVT Research on Botanical-Drug Interactions Published in Applied In Vitro Toxicology

By Lauren Vagnone | May 2, 2019

New BioIVT Research on Botanical-Drug Interactions Published in Applied In Vitro Toxicology

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that its ADME-Tox team has co-authored a second peer-reviewed paper investigating the potential for clinically-relevant botanical-drug interactions (BDIs) with toxicology colleagues at The Procter & Gamble Company (P&G).1 The paper describes a research collaboration by BioIVT and P&G based on studies conducted in BioIVT’s laboratory in Durham, NC.Read more

BioIVT Joins the Foundation for the National Institutes of Health Biomarkers Consortium

By Lauren Vagnone | March 25, 2019

BioIVT Joins the Foundation for the National Institutes of Health Biomarkers Consortium

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.Read more

BioIVT Webinar to Discuss Ethical and Regulatory Issues Regarding Use of Human Biospecimens in Life Sciences Research in the UK and EU

By Lauren Vagnone | March 18, 2019

Ethical and Regulatory Issues Regarding Use of Human Biospecimens in Life Sciences Research in the UK and EU

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be co-hosting a one-hour webinar entitled “Gaining Clarity: Unique Considerations for the Ethical and Regulatory Use of Human Biospecimens in the European Union (EU) and United Kingdom (UK)” at 8 a.m. EST on Mar. 19.
Read more